Javier Fernandez-Ruiz

Summary

Affiliation: Universidad Complutense
Country: Spain

Publications

  1. pmc Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?
    Javier Fernandez-Ruiz
    Departamento de Bioquimica y Biologia Molecular III, Instituto Universitario de Investigación en Neuroquímica, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    Br J Clin Pharmacol 75:323-33. 2013
  2. ncbi request reprint [Cannabinoid drugs for neurological diseases: what is behind?]
    Javier Fernandez-Ruiz
    Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Espana
    Rev Neurol 54:613-28. 2012
  3. ncbi request reprint Cannabinoid CB2 receptor: a new target for controlling neural cell survival?
    Javier Fernandez-Ruiz
    Department of Biochemistry and Molecular Biology, Faculty of Medicine, Complutense University, 28040 Madrid, Spain
    Trends Pharmacol Sci 28:39-45. 2007
  4. pmc Prospects for cannabinoid therapies in basal ganglia disorders
    Javier Fernandez-Ruiz
    Departamento de Bioquimica y Biologia Molecular III, Instituto Universitario de Investigación en Neuroquímica, Facultad de Medicina, Universidad Complutense, Madrid, Spain
    Br J Pharmacol 163:1365-78. 2011
  5. ncbi request reprint Role of CB2 receptors in neuroprotective effects of cannabinoids
    Javier Fernandez-Ruiz
    Department of Biochemistry and Molecular Biology, Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas CIBERNED, Faculty of Medicine, Complutense University, 28040 Madrid, Spain
    Mol Cell Endocrinol 286:S91-6. 2008
  6. ncbi request reprint Cannabinoids and gene expression during brain development
    Javier Fernandez-Ruiz
    Department of Biochemistry and Molecular Biology, Faculty of Medicine, Complutense University, Ciudad Universitaria s n, 28040 Madrid, Spain
    Neurotox Res 6:389-401. 2004
  7. ncbi request reprint Preface: cannabinoids as new tools for the treatment of neurological disorders
    Javier Fernandez-Ruiz
    Department of Biochemistry and Molecular Biology, Faculty of Medicine, Complutense University, Madrid 28040, Spain
    Mol Neurobiol 36:1-2. 2007
  8. doi request reprint The endocannabinoid system as a target for the treatment of neuronal damage
    Javier Fernandez-Ruiz
    Departamento de Bioquimica y Biologia Molecular III, Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas, Facultad de Medicina, Universidad Complutense, Ciudad Universitaria s n, 28040 Madrid, Spain
    Expert Opin Ther Targets 14:387-404. 2010
  9. ncbi request reprint Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders
    Javier Fernandez-Ruiz
    Departamento de Bioquímica y Biología Molecular and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Universidad Complutense, Madrid, Spain
    CNS Neurosci Ther 16:e72-91. 2010
  10. ncbi request reprint Endocannabinoids and basal ganglia functionality
    J Fernandez-Ruiz
    Departamento de Bioquimica y Biologia Molecular III, Facultad de Medicina, Universidad Complutense, Ciudad Universitaria s n, 28040 Madrid, Spain
    Prostaglandins Leukot Essent Fatty Acids 66:257-67. 2002

Collaborators

Detail Information

Publications68

  1. pmc Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?
    Javier Fernandez-Ruiz
    Departamento de Bioquimica y Biologia Molecular III, Instituto Universitario de Investigación en Neuroquímica, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    Br J Clin Pharmacol 75:323-33. 2013
    ..CBD acts not only through the endocannabinoid system, but also causes direct or indirect activation of metabotropic receptors for serotonin or adenosine, and can target nuclear receptors of the PPAR family and also ion channels...
  2. ncbi request reprint [Cannabinoid drugs for neurological diseases: what is behind?]
    Javier Fernandez-Ruiz
    Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Espana
    Rev Neurol 54:613-28. 2012
    ....
  3. ncbi request reprint Cannabinoid CB2 receptor: a new target for controlling neural cell survival?
    Javier Fernandez-Ruiz
    Department of Biochemistry and Molecular Biology, Faculty of Medicine, Complutense University, 28040 Madrid, Spain
    Trends Pharmacol Sci 28:39-45. 2007
    ....
  4. pmc Prospects for cannabinoid therapies in basal ganglia disorders
    Javier Fernandez-Ruiz
    Departamento de Bioquimica y Biologia Molecular III, Instituto Universitario de Investigación en Neuroquímica, Facultad de Medicina, Universidad Complutense, Madrid, Spain
    Br J Pharmacol 163:1365-78. 2011
    ....
  5. ncbi request reprint Role of CB2 receptors in neuroprotective effects of cannabinoids
    Javier Fernandez-Ruiz
    Department of Biochemistry and Molecular Biology, Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas CIBERNED, Faculty of Medicine, Complutense University, 28040 Madrid, Spain
    Mol Cell Endocrinol 286:S91-6. 2008
    ....
  6. ncbi request reprint Cannabinoids and gene expression during brain development
    Javier Fernandez-Ruiz
    Department of Biochemistry and Molecular Biology, Faculty of Medicine, Complutense University, Ciudad Universitaria s n, 28040 Madrid, Spain
    Neurotox Res 6:389-401. 2004
    ....
  7. ncbi request reprint Preface: cannabinoids as new tools for the treatment of neurological disorders
    Javier Fernandez-Ruiz
    Department of Biochemistry and Molecular Biology, Faculty of Medicine, Complutense University, Madrid 28040, Spain
    Mol Neurobiol 36:1-2. 2007
  8. doi request reprint The endocannabinoid system as a target for the treatment of neuronal damage
    Javier Fernandez-Ruiz
    Departamento de Bioquimica y Biologia Molecular III, Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas, Facultad de Medicina, Universidad Complutense, Ciudad Universitaria s n, 28040 Madrid, Spain
    Expert Opin Ther Targets 14:387-404. 2010
    ..Cannabinoids are also able to decrease local inflammatory events by acting on glial processes that regulate neuronal survival, and to restore blood supply by reducing vasocontriction produced by several endothelium-derived factors...
  9. ncbi request reprint Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders
    Javier Fernandez-Ruiz
    Departamento de Bioquímica y Biología Molecular and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Universidad Complutense, Madrid, Spain
    CNS Neurosci Ther 16:e72-91. 2010
    ..The present review will address the current literature supporting these cannabinoid-DA interactions, with emphasis in aspects dealing with the neurochemical, physiological, and pharmacological/therapeutic bases of these interactions...
  10. ncbi request reprint Endocannabinoids and basal ganglia functionality
    J Fernandez-Ruiz
    Departamento de Bioquimica y Biologia Molecular III, Facultad de Medicina, Universidad Complutense, Ciudad Universitaria s n, 28040 Madrid, Spain
    Prostaglandins Leukot Essent Fatty Acids 66:257-67. 2002
    ..This review will summarize our current knowledge on the role of these endogenous substances in the control of movement and, in particular, on the possible therapeutic usefulness of these compounds in the treatment of motor pathologies...
  11. ncbi request reprint UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders
    Eva de Lago
    Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    Eur Neuropsychopharmacol 16:7-18. 2006
    ....
  12. ncbi request reprint Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease
    Sara Gonzalez
    Department of Biochemistry and Molecular Biology, Faculty of Medicine, Complutense University, 28040 Madrid, Spain
    Brain Res 1073:209-19. 2006
    ..Therefore, the elucidation of the neurochemical substrate involved in this effect remains a major challenge for the future...
  13. ncbi request reprint Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease
    Isabel Lastres-Becker
    Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    Synapse 44:23-35. 2002
    ..These observations might be relevant to the treatment of hyperkinetic symptoms in HD, a human disorder with unsatisfactory symptomatic treatment for most patients...
  14. ncbi request reprint Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease
    Isabel Lastres-Becker
    Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    J Neurochem 84:1097-109. 2003
    ....
  15. ncbi request reprint Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence
    Eva de Lago
    Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad Complutense, Ciudad Universitaria s n, 28040 Madrid, Spain
    Brain Res 1007:152-9. 2004
    ..In vitro studies, using perifused striatal fragments, support this vanilloid-like receptor-mediated direct action, which would not be available for classic cannabinoid agonists...
  16. ncbi request reprint Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties
    Moisés García-Arencibia
    Departamento de Bioquimica y Biologia Molecular III, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    Brain Res 1134:162-70. 2007
    ..In addition, the activation of CB2 (but not CB1) receptors, or other additional mechanisms, might also contribute to some extent to the potential of cannabinoids in this disease...
  17. ncbi request reprint Region-dependent changes in endocannabinoid transmission in the brain of morphine-dependent rats
    Sara Gonzalez
    Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    Addict Biol 8:159-66. 2003
    ....
  18. ncbi request reprint Blockade of cannabinoid CB(1) receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity
    Henrik H Hansen
    Department of Biochemistry and Molecular Biology, Faculty of Medicine, Complutense University, Avenida de Complutense s n, 28040 Madrid, Spain
    J Neurochem 82:154-8. 2002
    ..These results suggest a critical involvement of CB(1) receptor tonus on neuronal survival following NMDA receptor-induced excitotoxicity in vivo...
  19. ncbi request reprint Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine
    Sara Gonzalez
    Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad Complutense, Ciudad Universitaria s n, 28040 Madrid, Spain
    Brain Res 954:73-81. 2002
    ....
  20. ncbi request reprint Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence
    Sara Gonzalez
    Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    Drug Alcohol Depend 74:159-70. 2004
    ..This is indicative of the existence of a withdrawal syndrome in cannabinoid-tolerant rats that is mild compared with abstinence in opioid-dependent rats...
  21. ncbi request reprint Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease
    Eva de Lago
    Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    Brain Res 1050:210-6. 2005
    ..Nevertheless, considering the lack of efficacious pharmacological treatments in this basal ganglia disorder, our findings might provide the basis for the development of more specific drugs against HD...
  22. ncbi request reprint UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide
    Eva de Lago
    Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    Eur J Pharmacol 449:99-103. 2002
    ..This compound is, thus, a promising tool, used alone or in combination with endocannabinoids, for the treatment of a variety of disorders...
  23. ncbi request reprint The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects
    Julian Romero
    Laboratorio de Apoyo a la Investigacion, Fundacion Hospital Alcorcon, Madrid, Spain
    Pharmacol Ther 95:137-52. 2002
    ..The present article will review the current knowledge of this neuromodulatory system, trying to establish the future lines for research on the therapeutic potential of the endocannabinoid system in motor disorders...
  24. ncbi request reprint Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis
    Ana Cabranes
    Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    Neurobiol Dis 20:207-17. 2005
    ....
  25. ncbi request reprint Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice
    Ana I Rojo
    Instituto de Investigaciones Biomédicas and Departamento de Bioquímica, Facultad de Medicina, Universidad Autonoma de Madrid, Arzobispo Morcillo 4, 28029 Madrid, Spain
    Eur J Neurosci 24:1874-84. 2006
    ..However, alpha-synuclein aggregation was not observed. This new animal model provides a new tool for studying PD symptoms that develop slowly over time, and it may be used to asses risk from environmental neurotoxins...
  26. doi request reprint Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease
    Cristina Blazquez
    Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas, Huntington s Disease and Ataxias Collaborative Project, 28040 Madrid, Spain
    Brain 134:119-36. 2011
    ....
  27. ncbi request reprint Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors
    Onintza Sagredo
    Departamento de Bioquimica y Biologia Molecular III, Universidad Complutense, 28040 Madrid, Spain
    Eur J Neurosci 26:843-51. 2007
    ..This capability seems to be based exclusively on the antioxidant properties of CBD...
  28. ncbi request reprint Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors
    María L Lopez-Rodriguez
    Departamento de Quimica Organica I, Facultad de Ciencias Quimicas, Universidad Complutense, 28040, Madrid, Spain
    Eur J Med Chem 38:403-12. 2003
    ..In vivo it enhances the analgesia and hypokinetic effects induced by a subeffective dose of anandamide...
  29. ncbi request reprint Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo
    Isabel Lastres-Becker
    Departamento de Bioquimica y Biologia Molecular III, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    Neuroreport 15:2375-9. 2004
    ..In conclusion, the present study supports the hypothesis that cannabinoid receptors, possibly the CB(1) receptor subtype, may be involved in HD pathogenesis and could be an interesting therapeutic target to slow disease progression...
  30. doi request reprint Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism
    Agnieszka Jazwa
    Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas CIBERNED, Madrid, Spain
    Antioxid Redox Signal 14:2347-60. 2011
    ..These results provide strong pharmacokinetic and biochemical evidence for activation of Nrf2 and phase II genes in the brain and also offer a neuroprotective strategy that may have clinical relevance for PD therapy...
  31. doi request reprint CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats
    Marina Rubio
    Departamento de Bioquímica y Biología Molecular and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    Neuropharmacology 54:976-88. 2008
    ....
  32. ncbi request reprint Neurochemical effects of the endocannabinoid uptake inhibitor UCM707 in various rat brain regions
    Eva de Lago
    Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    Life Sci 80:979-88. 2007
    ..By contrast, norepinephrine and serotonin were altered by UCM707 in the hypothalamus, cerebellum (only norepinephrine), and nucleus accumbens, exhibiting biphasic effects in some cases...
  33. ncbi request reprint Cannabinoid CB(1) receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice
    Sara Gonzalez
    Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain
    Brain Res 1046:195-206. 2005
    ....
  34. ncbi request reprint Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity
    Javier Palazuelos
    Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas CIBERNED, Spain
    Brain 132:3152-64. 2009
    ....
  35. ncbi request reprint Prenatal cannabinoid and gene expression for neural adhesion molecule L1 in the fetal rat brain
    Maria Gomez
    Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad Compultense de Madrid, Spain
    Brain Res Dev Brain Res 147:201-7. 2003
    ....
  36. pmc Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease
    Onintza Sagredo
    Departamento de Bioquímica y Biología Molecular and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas CIBERNED, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    Glia 57:1154-67. 2009
    ..Altogether, our results support the hypothesis that CB2 receptors could constitute a therapeutic target to slowdown neurodegeneration in HD...
  37. ncbi request reprint Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice
    Ana Cabranes
    Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    Brain Res 1107:199-205. 2006
    ..These observations may explain the efficacy of cannabinoid agonists to improve motor symptoms (spasticity, tremor, ataxia) typical of MS in both humans and animal models...
  38. ncbi request reprint Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease
    Isabel Lastres-Becker
    Departamento de Bioquimica y Biologia Molecular III, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    Neurobiol Dis 19:96-107. 2005
    ....
  39. doi request reprint Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease
    Onintza Sagredo
    Departamento de Bioquimica y Biologia Molecular, Instituto Universitario de Investigación en Neuroquímica, Universidad Complutense, Madrid, Spain
    J Neurosci Res 89:1509-18. 2011
    ....
  40. ncbi request reprint Effects of perinatal exposure to delta 9-tetrahydrocannabinol on operant morphine-reinforced behavior
    Begona Gonzalez
    Departamento de Psicobiologia, Facultad de Psicologia, Universidad Nacional de Educacion a Distancia, Ciudad Universitaria, 28040 Madrid, Spain
    Pharmacol Biochem Behav 75:577-84. 2003
    ....
  41. ncbi request reprint Cannabinoids and neuroprotection in basal ganglia disorders
    Onintza Sagredo
    Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina III, Universidad Complutense, Ciudad Universitaria s n, 28040 Madrid, Spain
    Mol Neurobiol 36:82-91. 2007
    ....
  42. ncbi request reprint Therapeutic potential of the endocannabinoid system in the brain
    Jose Antonio Ramos
    Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain
    Mini Rev Med Chem 5:609-17. 2005
    ....
  43. pmc Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors
    Sara Valdeolivas
    Departamento de Bioquimica y Biologia Molecular, Instituto Universitario de Investigación en Neuroquímica, Centro deInvestigación Biomédica en Red sobre Enfermedades Neurodegenerativas CIBERNED, and Instituto Ramón y Cajal deInvestigación Sanitaria IRYCIS, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    ACS Chem Neurosci 3:400-6. 2012
    ....
  44. doi request reprint Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects
    Eva de Lago
    Departamento de Bioquimica y Biologia Molecular, Instituto Universitario de Investigación en Neuroquímica, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    Neuropharmacology 62:2299-308. 2012
    ..This effect was exerted through the activation of CB(1) receptors, which would exert a positive influence in the reduction of inflammatory events linked to the pathogenesis of this disease...
  45. doi request reprint Description of a bivalent cannabinoid ligand with hypophagic properties
    Cristina Fernandez-Fernandez
    Instituto de Química Médica, CSIC, Madrid, Spain
    Arch Pharm (Weinheim) 346:171-9. 2013
    ..Moreover, intraperitoneal administration of 4d to food-deprived rats resulted in a dose-dependent inhibition of feeding that was maintained up to 240 min...
  46. ncbi request reprint In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake
    Eva de Lago
    Departamento de Bioquimica y Biologia Molecular III, Facultad de Medicina, Universidad Complutense, Ciudad Universitaria s n, Madrid 28040, Spain
    Eur J Pharmacol 484:249-57. 2004
    ....
  47. pmc Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats, and their possible relevance to alcohol relapse
    Sara Gonzalez
    Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad Complutense, Ciudad Universitaria s n, 28040 Madrid, Spain
    Br J Pharmacol 143:455-64. 2004
    ....
  48. ncbi request reprint Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase
    María L Lopez-Rodriguez
    Departamento de Quimica Organica I, Facultad de Ciencias Quimicas, Universidad Complutense, E 28040 Madrid, Spain
    J Med Chem 46:1512-22. 2003
    ..8 and 30 microM, respectively), will provide useful tools for the elucidation of the role of the anandamide transporter system in vivo...
  49. pmc Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol
    Marina Rubio
    Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    Neurosci Lett 421:270-4. 2007
    ..These results support the notion that short-term alcohol exposure reduces endocannabinoid levels in the brain accompanied by a reduction in several related N-acylethanolamines...
  50. ncbi request reprint Chronic Delta9-tetrahydrocannabinol administration affects serotonin levels in the rat frontal cortex
    Onintza Sagredo
    Department of Biochemistry and Molecular Biology, Faculty of Medicine, Complutense University, 28040, Madrid, Spain
    Naunyn Schmiedebergs Arch Pharmacol 372:313-7. 2006
    ....
  51. ncbi request reprint Down-regulation of the AMPA glutamate receptor subunits GluR1 and GluR2/3 in the rat cerebellum following pre- and perinatal delta9-tetrahydrocannabinol exposure
    Isabel Suarez
    Departamento Biología Celular y Genética, Universidad de Alcala, Madrid, Spain
    Cerebellum 3:66-74. 2004
    ....
  52. pmc Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1
    Nadia G Innamorato
    Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas CIBERNED, Instituto de Investigación Sanitaria La Paz IdiPaz, Madrid, Spain
    PLoS ONE 5:e11838. 2010
    ..Before targeting Nrf2 for PD therapy it is imperative to determine if HO-1 is neurotoxic or neuroprotective in the basal ganglia...
  53. doi request reprint Effects of a short-term exposure to alcohol in rats on FAAH enzyme and CB1 receptor in different brain areas
    Marina Rubio
    Department of Biochemistry and Molecular Biology and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Faculty of Medicine, Complutense University, 28040 Madrid, Spain
    Drug Alcohol Depend 99:354-8. 2009
    ..In any case, these observations would support the notion of a general reduction in the activity of the cannabinoid signaling system by acute alcohol exposure...
  54. pmc The endocannabinoid system as a target for the treatment of motor dysfunction
    Javier Fernandez-Ruiz
    Departamento de Bioquímica y Biología Molecular and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas CIBERNED, Facultad de Medicina, Universidad Complutense, Madrid, Spain
    Br J Pharmacol 156:1029-40. 2009
    ....
  55. pmc Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results
    Cristina Fernandez-Fernandez
    Instituto de Química Médica, CSIC, Madrid, Spain
    Drug Des Devel Ther 8:263-77. 2014
    ..Interestingly, in vivo, the new compounds exhibited a significant dual antagonist action on the endocannabinoid and opioid systems. ..
  56. ncbi request reprint Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels
    Eva de Lago
    Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    Biochem Pharmacol 70:446-52. 2005
    ....
  57. ncbi request reprint The activation of cannabinoid receptors during early postnatal development reduces the expression of cell adhesion molecule L1 in the rat brain
    Maria Gomez
    Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad Complutense de Madrid, 28040 Madrid, Spain
    Brain Res 1145:48-55. 2007
    ....
  58. ncbi request reprint Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: relevance for in vitro studies with cannabinoids in motor neuron diseases
    Miguel Moreno-Martet
    Departamento de Bioquimica y Biologia Molecular, Instituto Universitario de Investigación en Neuroquímica, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    Neurosci Lett 508:67-72. 2012
    ....
  59. ncbi request reprint Cannabinoids: novel medicines for the treatment of Huntington's disease
    Onintza Sagredo
    Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    Recent Pat CNS Drug Discov 7:41-8. 2012
    ..The present review will address all preclinical evidence supporting the potential of Sativex® for the treatment of disease progression in HD patients. The article presents some promising patents on the cannabinoids...
  60. pmc A restricted population of CB1 cannabinoid receptors with neuroprotective activity
    Anna Chiarlone
    Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas, Instituto Ramón y Cajal de Investigación Sanitaria, 28040 Madrid, Spain Department of Biochemistry and Molecular Biology I, Instituto Universitario de Investigación Neuroquímica, Complutense University, 28040 Madrid, Spain
    Proc Natl Acad Sci U S A 111:8257-62. 2014
    ....
  61. ncbi request reprint Cannabinoids and Parkinson's disease
    Moisés García-Arencibia
    Departamento de Bioquímica y Biología Molecular and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas CIBERNED, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    CNS Neurol Disord Drug Targets 8:432-9. 2009
    ....
  62. ncbi request reprint Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB(1) receptor binding and mRNA levels
    Sara Gonzalez
    Departamento de Bioquijmica y Biologija Molecular, Facultad de Medicina, Universidad Complutense, 2804, Madrid, Spain
    Drug Alcohol Depend 66:77-84. 2002
    ..Alcohol did not produce any effects on CB(1) receptor binding and mRNA levels, whereas cocaine only affected transcript levels in selected regions and morphine produced divergent and region-dependent effects...
  63. ncbi request reprint Cannabinoids and neuroprotection in motor-related disorders
    Eva de Lago
    Departamento de Bioquímica y Biología Molecular and Centro de Investigación en Red sobre Enfermedades Neurodegenerativas CIBERNED, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    CNS Neurol Disord Drug Targets 6:377-87. 2007
    ..This should serve to encourage that the present promising evidence obtained mainly at the preclinical level might progress to a real exploitation of neuroprotective benefits of potential cannabinoid-based medicines...
  64. doi request reprint Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats
    Moisés García-Arencibia
    Department of Biochemistry and Molecular Biology, Faculty of Medicine, Complutense University, 28040 Madrid, Spain
    Neurosci Lett 438:10-3. 2008
    ..This observation is of potential clinical interest, particularly for those parkinsonian patients that exhibit a poor response to classic levodopa treatment...
  65. ncbi request reprint Cannabinoid tolerance and dependence: a review of studies in laboratory animals
    Sara Gonzalez
    Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    Pharmacol Biochem Behav 81:300-18. 2005
    ..The present review article will address all these aspects trying to establish the bases for future research...
  66. doi request reprint The endocannabinoid system in neuropathological states
    José Martínez Orgado
    Laboratorio de Apoyo a la Investigacion, Fundacion Hospital Alcorcon CIBERNED, Madrid, Spain
    Int Rev Psychiatry 21:172-80. 2009
    ....
  67. ncbi request reprint Cannabinoids, multiple sclerosis and neuroprotection
    Eva de Lago
    Departamento de Bioquímica y Biología Molecular and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas CIBERNED, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    Expert Rev Clin Pharmacol 2:645-60. 2009
    ....
  68. pmc Cannabinoid signaling system: does it play a function in cell proliferation and migration, neuritic elongation and guidance and synaptogenesis during brain ontogenesis?
    Maria Gomez
    Departamento de Bioquímica y Biología Molecular and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas CIBERNED, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
    Cell Adh Migr 2:246-8. 2008
    ..The present commentary will address these two questions trying to summarize all the available evidence and to suggest the future directions for research...